Von Willebrand Factor/thrombocytes (VITRO Score) and its diagnostic role as a non-invasive predictor of decompensation, mortality and portal hypertension in patients with compensated liver cirrhosis

Abstract Background Ruptured esophageal varices (EVs) are a leading cause of death in Portal hypertension (PHT), it has been a big concern of research to screen EVs through non-invasive approaches. This study aimed to evaluate the role of plasma von Willebrand factor antigen (VWF-Ag) assay for early detection of EVs in patients with portal hypertension. This was a cross-sectional study, done on 47 portal hypertensive children and adolescents who were collected from the Pediatrics Hepatology Clinic, Children Hospital, Ain Shams University. All patients were subjected to comprehensive history taking, thorough clinical examination, routine investigations, abdominal ultrasound, upper GI endoscopy, and measurement of plasma VWF-Ag level. The patients were divided based on their endoscopic findings into two groups; a varices group which included 37 patients, and a non-varices group which included 10 patients. Results VWF-Ag rise significantly in patients with EVs, revealing a direct positive association with the degree of EVs. Conclusion The plasma VWF-Ag can be applied as a non-invasive evidence of the presence and grading of EVs.

Download Full-text

Mo2081 Von Willebrand Factor as a New Noninvasive Predictor of Clinically Significant Portal Hypertension and Mortality in Liver Cirrhosis

Gastroenterology ◽

10.1053/j.gastro.2012.07.082 ◽

2012 ◽

Vol 143 (3) ◽

pp. e26

Author(s):

Monika Ferlitsch ◽

Thomas Reiberger ◽

Matthias Hoke ◽

Petra Salzl ◽

Gregor Ulbrich ◽

...

Keyword(s):

Liver Cirrhosis ◽

Portal Hypertension ◽

Von Willebrand Factor ◽

Clinically Significant ◽

Von Willebrand ◽

Willebrand Factor

Download Full-text

ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension

Case Medical Research ◽

10.31525/ct1-nct04267406 ◽

2020 ◽

Author(s):

Keyword(s):

Portal Hypertension ◽

Von Willebrand Factor ◽

Von Willebrand ◽

Willebrand Factor

Download Full-text

Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute‐on‐chronic liver failure development and prognosis in patients with liver cirrhosis

Hepatology Research ◽

10.1111/hepr.13743 ◽

2021 ◽

Author(s):

Masahide Enomoto ◽

Hiroaki Takaya ◽

Tadashi Namisaki ◽

Yukihisa Fujinaga ◽

Norihisa Nishimura ◽

...

Keyword(s):

Liver Cirrhosis ◽

Liver Failure ◽

Von Willebrand Factor ◽

Chronic Liver ◽

Adamts13 Activity ◽

Chronic Liver Failure ◽

Von Willebrand Factor Antigen ◽

Von Willebrand ◽

Willebrand Factor ◽

Factor Antigen

Download Full-text

von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2018-025656 ◽

2019 ◽

Vol 9 (8) ◽

pp. e025656

Author(s):

Ziyuan Zou ◽

Xinwen Yan ◽

Cheng Li ◽

Xiaofeng Li ◽

Xiaofen Ma ◽

...

Keyword(s):

Systematic Review ◽

Portal Hypertension ◽

Correlation Coefficient ◽

Von Willebrand Factor ◽

Diagnostic Performance ◽

Meta Analysis ◽

Moderate Correlation ◽

Clinically Significant ◽

Von Willebrand ◽

Willebrand Factor

ObjectiveThis meta-analysis was performed to investigate the correlation between von Willebrand factor (vWF) antigen and hepatic venous pressure gradient (HVPG) and to evaluate the diagnostic performance of vWF to detect clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH).DesignSystematic review and meta-analysis.MethodsMEDLINE, EMBASE, Web of Science and the Cochrane Library were screened up to 5 April 2018. Studies related to the diagnostic performance of vWF to detect CSPH and/or SPH with HVPG as the reference standard were included. Study quality was assessed by using the Quality Assessment of Diagnostic Accuracy Studies scale. Two authors independently used a standardised form to extract data.OutcomesThe primary outcome was the correlation coefficient between vWF and HVPG. The secondary outcome was the diagnostic performance of vWF to detect CSPH or SPH.ResultsA total of six articles involving 994 patients were included in this study. Five of the included articles were used to stratify the results for the correlation coefficient, three for the diagnostic performance of CSPH and two for SPH. The pooled correlation coefficient based on the random effects model was 0.54 (95% CI 0.35 to 0.69), thus suggesting a moderate correlation between vWF and HVPG. The pooled sensitivity, specificity and area under the curve of vWF for CSPH detection were 82% (95% CI 78 to 86), 76% (95% CI 68 to 83) and 0.87 (95% CI 0.80 to 0.94), respectively. Regarding the ability of vWF to detect SPH, the pooled sensitivity and specificity were 86% (95% CI 80 to 90) and 75% (95% CI 66 to 83), respectively. These results supported the satisfactory diagnostic performance of vWF for CSPH and SPH detection.ConclusionsvWF, as a novel biomarker, has a moderate correlation with HVPG and shows a satisfactory performance for the diagnosis of CSPH and SPH in patients with cirrhosis.

Download Full-text